Table 1.
Patient characteristics and operation details.
| Variables | Control group (n = 45) | DEX group (n = 46) | P value |
|---|---|---|---|
| age (years) | 52.2 (8.2) | 51.4 (9.6) | 0.641 |
| body mass index (kg/m) | 25.2 (3.9) | 23.8 (3.4) | 0.067 |
| diabetes mellitus | 8 (17.8%) | 7 (15.2%) | 0.742 |
| ASA class I/II/III | 21/13/11 | 24/17/4 | 0.135 |
| cancer type | |||
| cervix | 9 (20.0%) | 16 (34.8%) | 0.201 |
| endometrium | 33 (73.3%) | 29 (63.0%) | |
| myosarcoma | 3 (6.7%) | 1 (2.2%) | |
| operation | |||
| total hysterectomy | 14 (31.1%) | 8 (17.4%) | |
| total hysterectomy with salpingo-oophorectomy | 19 (42.2%) | 20 (43.5%) | 0.240 |
| radical hysterectomy | 12 (26.7%) | 18 (39.1%) | |
| lymph node sampling | 7 (15.6%) | 5 (10.9%) | 0.509 |
| Cancer (FIGO) stage I/II/III/IV; | 35/1/6/3 | 41/3/2/0 | 0.091 |
| Preoperative neoadjuvant therapy | 0 | 0 | |
| Postoperative chemotherapy | 16 (35.6%) | 9 (19.6%) | 0.088 |
| Postoperative radiotherapy | 15 (33.3%) | 12 (26.1%) | 0.449 |
| Postoperative hormone therapy | 0 | 0 | |
| duration of operation (min) | 194.3 (82.0) | 175.2 (60.8) | 0.211 |
| duration of anesthesia (min) | 230.1 (85.0) | 209.0 (62.0) | 0.180 |
| propofol (mg/kg) | 1.4 (0.3) | 1.4 (0.2) | 0.477 |
| remifentanil (μg/kg/min) | 0.06 (0.02) | 0.05 (0.02) | 0.004 |
| bleeding (ml) | 50 (20–100) | 50 (30–100) | 0.913 |
| patients receiving erythrocyte transfusion | 3 (6.7%) | 2 (4.3%) | 0.628 |
Values are mean (standard deviation), number (percent), or median (interquartile range). ASA class, American Society of Anesthesiologists physical status classification; FIGO staging, International Federation of Gynecology and Obstetrics staging.